ASPEN PHARMACARE HOLDINGS LIMITED - Aspen to enter strategic collaboration with GlaxoSmithKline in Japan

Aspen to enter strategic collaboration with GlaxoSmithKline in Japan

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
and its subsidiaries (collectively “Aspen” or “the Group”)

ASPEN TO ENTER STRATEGIC COLLABORATION WITH GLAXOSMITHKLINE IN JAPAN

Aspen is pleased to announce that Aspen Global Incorporated (“AGI”), a wholly owned subsidiary of Aspen
Holdings Incorporated (the Group), has entered into an agreement with GlaxoSmithKline (“GSK”) whereby
GSK will take an equity stake in Aspen’s newly established subsidiary in Japan named Aspen Japan K.K.
(“Aspen Japan”). In terms of this agreement Aspen will hold a 75% equity share in Aspen Japan, while GSK
will hold a 25% share. It is intended that Aspen Japan will, where feasible, be the conduit through which
the Group will conduct its commercial operations in Japan in a strategic alliance with GSK. The
collaboration will be operated in accordance with the following salient terms:

 -   AGI will transfer the marketing authorisations and grant perpetual distribution rights to Aspen Japan
     for all products currently being marketed and distributed on behalf of Aspen in Japan;

 -  GSK will transfer the marketing authorisations and grant distribution rights to Aspen Japan for certain
     mature products in GSK’s portfolio;

 -   GSK will provide Aspen Japan with a pipeline of authorised generics for a number of GSK’s products;

 -   AGI will offer Aspen Japan the rights to all future products that it acquires or licenses in Japan; and

 -   AGI will be responsible for the management of Aspen Japan and for the commercialization of all the
     products in Aspen Japan’s portfolio.


Completion of this agreement will be subject to a number of conditions precedent, one of which is Aspen
Japan obtaining accreditation as a Marketing Authorisation Holder from the relevant Japanese regulatory
authority.

It is expected that, through this agreement with GSK, Aspen will be able to harness more opportunities and
grow its presence in one of the world’s biggest pharmaceutical markets.

Durban

9 October 2014

Sponsor:

Investec Bank Limited

Date: 09/10/2014 07:05:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.